keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant

keyword
https://www.readbyqxmd.com/read/29791816/fast-forward-neoadjuvant-cancer-immunotherapy
#1
EDITORIAL
Thomas F Gajewski
New England Journal of Medicine, Volume 378, Issue 21, Page 2034-2035, May 2018.
May 24, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29791703/biological-intercalary-reconstruction-with-bone-grafts-after-joint-sparing-resection-of-the-lower-limb-is-this-an-effective-and-durable-solution-for-joint-preservation
#2
Francesco Muratori, Francesca Totti, Antonio D'Arienzo, Maurizio Scorianz, Guido Scoccianti, Giovanni Beltrami, Francesco Rosario Campo, Carmine Citarelli, Rodolfo Capanna, Domenico Andrea Campanacci
Due to advances in neoadjuvant therapies and preoperative imaging modalities, joint-sparing resections have become appealing in bone tumor surgery. However, the intercalary reconstruction of metadiaphyseal bone defects of the femur and the tibia after juxta-articular tumor resection remains challenging. Both biological and prosthetic reconstructions have been used for joint-sparing resections, but little is known about the long-term outcome of these procedures. The authors reviewed a consecutive series of 64 patients treated with joint-sparing intercalary resection and reconstruction with bone grafts...
June 1, 2018: Surgical Technology International
https://www.readbyqxmd.com/read/29791660/potential-role-of-sorafenib-as-neoadjuvant-therapy-in-unresectable-papillary-thyroid-cancer
#3
Debora L S Danilovic, Gilberto Castro, Felipe S R Roitberg, Felipe A B Vanderlei, Fernanda A Bonani, Ricardo M C Freitas, George B Coura-Filho, Rosalinda Y Camargo, Marco A Kulcsar, Suemi Marui, Ana O Hoff
Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy...
May 17, 2018: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29791416/oncological-outcomes-in-extended-time-intervals-betweenpreoperative-chemoradiotherapy-with-capecitabine-and-surgery-inoperable-rectal-adenocarcinoma
#4
Miguel A Muñoz, Manuel G Palacios, Jenny Malca, Raúl Mantilla, Paola C Montenegro, Ivan Chavez
OBJECTIVE: To assess whether extended time intervals (8-12, 13-20 and >20 weeks) between the end of neoadjuvant chemoradiotherapy and surgery affect overall survival, disease-free survival. MATERIALS AND METHODS: Retrospective study in 120 patients with rectal adenocarcinoma without evidence of metastasis (T1-4/N0-2/M0) at the time of diagnosis that underwent surgery with curative intent after neoadjuvant chemoradiotherapy with capecitabine and obtained R0 or R1 resection between January 2010 to December 2014 at the National Cancer Institute of Peru...
January 2018: Revista de Gastroenterología del Perú: órgano Oficial de la Sociedad de Gastroenterología del Perú
https://www.readbyqxmd.com/read/29791287/brca1-2-mutations-and-bevacizumab-in-the-neoadjuvant-treatment-of-breast-cancer-response-and-prognosis-results-in-patients-with-triple-negative-breast-cancer-from-the-geparquinto-study
#5
Peter A Fasching, Sibylle Loibl, Chunling Hu, Steven N Hart, Hermela Shimelis, Raymond Moore, Christian Schem, Hans Tesch, Michael Untch, Jörn Hilfrich, Mahdi Rezai, Bernd Gerber, Serban Dan Costa, Jens-Uwe Blohmer, Tanja Fehm, Jens Huober, Cornelia Liedtke, Richard M Weinshilboum, Liewei Wang, James N Ingle, Volkmar Müller, Valentina Nekljudova, Karsten E Weber, Brigitte Rack, Matthias Rübner, Gunter von Minckwitz, Fergus J Couch
Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study...
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29790787/colorectal-liver-metastases-a-pathologist-s-guide-to-creating-an-informative-report-and-improving-patient-care
#6
Mariana Moreno Prats, Eizaburo Sasatomi, Heather L Stevenson
CONTEXT: - In this era of minimally invasive procedures for diagnosis, prognosis, and treatment, pathologists are at the forefront of analyzing specimens and are expected to make more specific diagnoses, providing additional information from the material they receive. OBJECTIVE: - To familiarize pathologists with the essential components of surgical pathology reports for colorectal liver metastases (CRLM) resections. DATA SOURCES: - Colorectal cancer is the third most common cancer in the world and the liver is the most frequent site of metastases...
May 23, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29790087/correlation-between-clinical-and-pathologic-staging-in-colon-cancer-implications-for-neoadjuvant-treatment
#7
Ahmed N Dehal, Amanda N Graff-Baker, Brooke Vuong, Daniel Nelson, Shu-Ching Chang, David Y Lee, Melanie Goldfarb, Anton J Bilchik
BACKGROUND: Recent randomized trials suggest improved outcomes in patients with locally advanced colon cancer (LACC) treated with neoadjuvant chemotherapy (NAC). Optimal selection of patients for NAC depends on accurate clinical staging. The purpose of this study was to examine the degree of correlation between clinical and pathologic staging in patients with colon cancer (CC). METHODS: Adult patients with non-metastatic CC who underwent surgery were identified from the National Cancer Data Base between 2006 and 2014...
May 22, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29789768/radiological-and-clinical-findings-following-rectal-contact-x-ray-brachytherapy-papillon-technique-how-to-assess-response
#8
Matt J D Dunstan, Tim A Rockall, Kate Potter, Alexandra J Stewart
Purpose: Rectal contact X-ray brachytherapy (Papillon radiotherapy) has recently received approval from the National Institute for Health and Care Excellence. In particular, it is suitable for elderly patients who are high-risk for a major operation, but it may also be undertaken for patients who wish to avoid a stoma. It is imperative to be able to identify clinical response or tumor regrowth on surveillance magnetic resonance imaging (MRI) and sigmoidoscopy. This article aims to help clinicians to interpret MRIs and endoscopic appearances following Papillon radiotherapy...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29789701/neoadjuvant-folfirinox-improves-outcomes
#9
Peter Sidaway
No abstract text is available yet for this article.
May 22, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29788989/loop-ostomy-following-laparoscopic-low-anterior-resection-for-rectal-cancer-after-neoadjuvant-chemoradiotherapy
#10
Xin Wu, Guole Lin, Huizhong Qiu, Yi Xiao, Bin Wu, Miner Zhong
BACKGROUND: Both loop ileostomy (LI) and loop transverse colostomy (LTC) could achieve absolute fecal diversion and have several advantages. This study compared LI and LTC following laparoscopic low anterior resection for rectal cancer after neoadjuvant chemoradiotherapy. METHODS: Between January 2009 and December 2016, 186 patients who underwent laparoscopic low anterior resection for rectal cancer and loop ostomy were included. All patients received preoperative neoadjuvant chemoradiotherapy...
May 22, 2018: European Journal of Medical Research
https://www.readbyqxmd.com/read/29788230/tumor-infiltrating-lymphocytes-in-patients-receiving-trastuzumab-pertuzumab-based-chemotherapy-a-tryphaena-substudy
#11
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, Marco Fornili, Yacine Bareche, Christine Desmedt, Françoise Rothé, Marion Maetens, David Venet, Esther Holgado, Virginia McNally, Astrid Kiermaier, Heidi M Savage, Timothy R Wilson, Javier Cortes, Andreas Schneeweiss, Karen Willard-Gallo, Elia Biganzoli, Christos Sotiriou
Background: There is an urgent requirement to identify biomarkers to tailor treatment in human epidermal growth factor receptor 2 (HER2)-amplified early breast cancer treated with trastuzumab/pertuzumab-based chemotherapy. Methods: Among the 225 patients randomly assigned to trastuzumab/pertuzumab concurrently or sequentially with an anthracycline-containing regimen or concurrently with an anthracycline-free regimen in the Tryphaena trial, we determined the percentage of tumor-infiltrating lymphocytes (TILs) at baseline in 213 patients, of which 126 demonstrated a pathological complete response (pCR; ypT0/is ypN0), with 28 demonstrating event-free survival (EFS) events...
May 18, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29787740/conservative-management-following-clinical-complete-response-to-neoadjuvant-chemotherapy-for-muscle-invasive-bladder-cancer-contemporary-outcomes-of-a-multi-institutional-cohort-study
#12
Patrick Mazza, George W Moran, Gen Li, Dennis J Robins, Justin T Matulay, Harry W Herr, Guarionex J Decastro, James M McKiernan, Christopher B Anderson
PURPOSE: We report the outcomes of patients with muscle-invasive bladder cancer from two institutions who experienced a clinical complete response to neoadjuvant platinum-based chemotherapy and opted for active surveillance. It is unknown if conservative management can be safely implemented in these patients. MATERIALS AND METHODS: We performed a retrospective review of patients at Columbia University Medical Center and Memorial Sloan Kettering Cancer Center with muscle-invasive bladder cancer who elected surveillance following a clinical complete response to transurethral resection of bladder tumors and neoadjuvant chemotherapy from 2001-2017...
May 19, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29786482/human-epidermal-growth-factor-2-positive-breast-cancer-with-mammographic-microcalcification-relationship-to-pathologic-complete-response-after-neoadjuvant-chemotherapy
#13
Fayyaz A K Mazari, Nisha Sharma, David Dodwell, Kieran Horgan
Purpose To determine the relationship between the presence or absence of mammographic calcifications in human epidermal growth factor receptor 2 (HER2)-positive breast cancers and pathologic complete response (pCR) to neoadjuvant chemotherapy and to determine other tumor and clinical characteristics that may be predictive of such a response. Materials and Methods A database of all patients with HER2-positive breast cancer who underwent neoadjuvant chemotherapy between 2007 and 2015 was retrospectively reviewed...
May 16, 2018: Radiology
https://www.readbyqxmd.com/read/29786125/neoadjuvant-chemotherapy-use-in-breast-cancer-is-greatest-in-excellent-responders-triple-negative-and-her2-subtypes
#14
Brittany L Murphy, Courtney N Day, Tanya L Hoskin, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: While breast cancer has historically been treated with surgery followed by adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy (NAC) use is thought to be increasing; however, the trends of its use in various biological subtypes have not been evaluated. We sought to evaluate the trend of NAC use over time by biological subtype. METHODS: We identified all patients with invasive breast cancer who underwent curative intent surgery and were treated with chemotherapy from 2010 to 2015 from the National Cancer Database...
May 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29785081/pressurized-intraperitoneal-aerosol-chemotheprapy-after-misdiagnosed-gastric-cancer-case-report-and-review-of-the-literature
#15
Maciej Nowacki, Dariusz Grzanka, Wojciech Zegarski
We report the first application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a rescue therapy before palliative D2 gastrectomy combined with liver metastasectomy performed in a 49-year-old woman with peritoneal carcinomatosis who was primarily diagnosed with and underwent surgery for a Krukenberg tumor. The PIPAC procedure was performed with the use of cisplatin at 7.5 mg/m2 and doxorubicin at 1.5 mg/m2 for 30 min at 37 °C. Eight weeks after the PIPAC procedure, the patient underwent open classic D2 gastrectomy with the creation of a Roux-en-Y anastomosis (RNY) combined with liver metastasectomy...
May 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29785080/prognostic-impact-of-the-red-cell-distribution-width-in-esophageal-cancer-patients-a-systematic-review-and-meta-analysis
#16
Wei-Yu Xu, Xiao-Bo Yang, Wen-Qin Wang, Yi Bai, Jun-Yu Long, Jian-Zhen Lin, Jian-Ping Xiong, Yong-Chang Zheng, Xiao-Dong He, Hai-Tao Zhao, Xin-Ting Sang
AIM: To clarify the previous discrepant conclusions, we performed a meta-analysis to evaluate the prognostic value of red cell distribution width (RDW) in esophageal cancer (EC). METHODS: We searched the PubMed, EMBASE, Web of Science and Cochrane Library databases to identify clinical studies, followed by using STATA version 12.0 for statistical analysis. Studies that met the following criteria were considered eligible: (1) Studies including EC patients who underwent radical esophagectomy; (2) studies including patients with localized disease without distant metastasis; (3) studies including patients without preoperative neoadjuvant therapy; (4) studies including patients without previous antiinflammatory therapies and with available preoperative laboratory outcomes; (5) studies reporting association between the preoperative RDW and overall survival (OS)/disease-free survival (DFS)/cancer-specific survival (CSS); and (6) studies published in English...
May 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29784739/management-of-locoregional-rectal-cancer
#17
Christopher G Willett
The NCCN Guidelines for Rectal Cancer are now more closely aligned with those for colon cancer. A new MRI-based definition of the rectum has been included and the use of MRI in staging has been elevated in importance. There is a new emphasis on neoadjuvant therapy, especially the concurrent use of chemotherapy and radiotherapy. One of the biggest changes is more acceptance of an observational approach-"watch and wait, nonoperative management"-for select patients experiencing a complete clinical response with no evidence of residual disease after neoadjuvant therapy...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29784042/neoadjuvant-oxaliplatin-and-capecitabine-combined-with-bevacizumab-plus-radiotherapy-for-locally-advanced-rectal-cancer-results-of-a-single-institute-phase-ii-study
#18
Xin Yu, Qiao-Xuan Wang, Wei-Wei Xiao, Hui Chang, Zhi-Fan Zeng, Zhen-Hai Lu, Xiao-Jun Wu, Gong Chen, Zhi-Zhong Pan, De-Sen Wan, Pei-Rong Ding, Yuan-Hong Gao
BACKGROUND: Neoadjuvant chemoradiotherapy followed by surgery is recommended as the standard of care for locally advanced rectal cancer, reducing local recurrence but not distant metastasis. Intensified systemic therapy is warranted to reduce the risk of distant metastasis. The present study aimed to evaluate the safety and efficacy of neoadjuvant oxaliplatin and capecitabine (XELOX) combined with bevacizumab plus radiotherapy for locally advanced rectal cancer. METHODS: Patients with stages II to III rectal cancer received one cycle of induction chemotherapy and concurrent chemoradiotherapy with XELOX plus bevacizumab...
May 21, 2018: Cancer communications
https://www.readbyqxmd.com/read/29783590/re-impact-of-suboptimal-neoadjuvant-chemotherapy-on-peri-operative-outcomes-and-survival-after-robot-assisted-radical-cystectomy-a-multicentre-multinational-study
#19
https://www.readbyqxmd.com/read/29782362/breast-conservation-therapy-after-neoadjuvant-chemotherapy-does-not-compromise-10-year-breast-cancer-specific-mortality
#20
Renee L Arlow, Lisa E Paddock, Xiaoling Niu, Laurie Kirstein, Bruce G Haffty, Sharad Goyal, Thomas Kearney, Deborah Toppmeyer, Antoinette M Stroup, Atif J Khan
OBJECTIVES: Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery by downstaging disease in patients with breast cancer. The aim of this study was to determine whether patients who received neoadjuvant chemotherapy have equal survival after breast-conservation therapy compared with mastectomy. MATERIAL AND METHODS: Using the New Jersey State Cancer Registry (NJSCR) patients with a primary breast cancer diagnosed between 1998 and 2003 who underwent neoadjuvant chemotherapy were selected (n=1,468)...
May 18, 2018: American Journal of Clinical Oncology
keyword
keyword
29246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"